摘要
目的探讨吉西他滨联合顺铂对肺癌的临床治疗效果及安全性评估。方法选取2017年1月-2018年2月在广州军区广州总医院住院治疗的肺癌患者90例,采用随机数字法分为对照组和观察组,每组各45例。对照组患者给予多西他赛联合顺铂进行化疗,观察组患者给予吉西他滨联合顺铂进行化疗。观察两组患者的临床治疗有效率、疾病控制率及不良反应发生率,并比较化疗前后两组的QOL评分及KPS评分。结果治疗后,观察组治疗有效率和疾病控制率分别为84.44%和91.11%,对照组患者的治疗有效率和疾病控制率分别为62.22%和73.33%,差异具有统计学意义(P<0.05)。治疗后,两组QOL评分及KPS评分均升高,同组治疗前后比较差异具有统计学意义(P<0.05),且观察组患者的QOL评分及KPS评分均显著高于对照组,两组比较差异具有统计学意义(P<0.05)。两组患者在胃肠道反应、骨髓抑制、血小板减少、乏力、贫血及发热等不良反应上相比,差异无统计学意义。结论吉西他滨联合顺铂治疗肺癌的临床效果较好,且安全性较高,值得推广应用。
Objective To investigate the clinical therapeutic effect and safety asserrment of gemcitabine combined with cisplatin in treatment of lung cancer. Methods Patients(90 cases) with lung cancer in General Hospital of Guangzhou Military Command from January 2017 to February 2018 were divided into control group and observation group, according to random number method, and each group had 45 cases. Patients in control group was given docetaxel combined with cisplatin by chemotherapy, patients in the observation group was given gemcitabine combined with cisplatin by chemotherapy. The clinical efficiency, disease control rate, and adverse reaction rate in two groups were observed, and QOL score and KPS score before and after chemotherapy were compared.Results After treatment, the effective clinical treatment and disease control rate in the observation group were 84.44% and 91.11%,respectively, and the effective clinical treatment and disease control rate in the control group were 62.22% and 73.33%, respectively,the difference was statistically significant(P < 0.05). Before treatment, the QOL score and KPS score in two groups were significantly increased, and there were differences in the same group(P < 0.05). And the QOL score and KPS score in the observation group were significantly higher than those in the control group, and there were differences between two groups(P <0.05). Compared with the adverse reaction such as gastrointestinal reaction, myelosuppression, thrombocytopenia, weak, anemia and fever between two groups, the difference was not statistically significant. Conclusion Gemcitabine combined with cisplatin has good effect in treatment of lung cancer, and the safety is high, worthy of promotion and application.
作者
廖明
徐志勇
彭丽君
LIAO Ming;XU Zhiyong;PENG Lijun(Department of Thoracic Surgery,General Hospital of Guangzhou Military Command,Guangzhou 510010,China;Department of Oncology,General Hospital of Guangzhou Military Command,Guangzhou 510010,China)
出处
《药物评价研究》
CAS
2019年第10期2012-2015,共4页
Drug Evaluation Research
关键词
吉西他滨
顺铂
多西他赛
肺癌
疗效
安全性
gemcitabine
cisplatin
docetaxel
lung cancer
clinical effect
safety
